Met Non Small Cell Cancer Registry (MOMENT)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Austria, Belgium, Canada, Czechia +9
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Overview
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Detailed description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Primary outcome measures
- Best Overall Response (BOR) [Time frame: Through study completion, up to approximately 4.9 years]
- Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 [Time frame: Up to approximately 4.9 years]
- Overall Survival (OS) [Time frame: Through study completion, up to approximately 4.9 years]
- Number of Participants with Adverse Events (AEs) [Time frame: Up to approximately 4.9 years]
- Number of Participants with Adverse Reactions (ARs) [Time frame: Up to approximately 4.9 years]
Eligibility criteria
Inclusion criteria
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
Exclusion criteria
- Participants who are enrolled in a clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
United Kingdom · 10 centers
- Huddersfield Royal Infirmary — Huddersfield
- Bedford General Hospital — Bedford
- Birmingham Heartlands Hospital — Birmingham
- Royal Bournemouth Hospital — Bournemouth
- The Royal Marsden Hospital — Chelsea
- Northwick Park Hospital — Harrow
- Clatterbridge Cancer Centre - Liverpool — Liverpool
- Guy's Cancer Centre — London
- … and 2 more centers
Spain · 9 centers
- Clinica Tres Torres — Barcelona
- Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. R — Barcelona
- Complejo Hospitalario Universitario Insular-Materno Infantil — Las Palmas de Gran Canaria
- Centro Integral Oncologico Clara Campa — Madrid
- Centro Oncologico MD Anderson — Madrid
- Hospital Regional Universitario de Malaga - Hospital General — Málaga
- Hospidal Universitario Ntra. Sra. De Valme — Seville
- Hospital Universitario Virgen Macarena — Seville
- … and 1 more center
France · 8 centers
- Centre Hospitalier de Cholet — Cholet
- CHRU Lille — Lille
- Hôpital du Scorff — Lorient
- Centre Leon Berard — Lyon
- Hospital Tenon & University Paris 6 — Paris
- Institut Curie - Centre de Lutte Contre le Cancer (CLCC) — Paris
- CHU de Pontchaillou — Rennes
- CHU de Toulouse Hopital Larrey — Toulouse
Israel · 8 centers
- Haemek Medical Center — Afula
- Bnei-Zion Medical Center — Haifa
- Carmel Medical Center — Haifa
- Rambam Medical Center - PPDS — Haifa
- Shaare Zedek Medical Center — Jerusalem
- Rabin Medical Center Oncology Beilinson Campus — Petah Tikva
- Chaim Sheba Medical Center — Ramat Gan
- Tel Aviv Sourasky Medical Center — Tel Aviv
Italy · 8 centers
- Istituto Europeo di Oncologia — Milan
- Istituto Nazionale Dei Tumori — Milan
- Azienda Ospedaliero Universitaria di Modena — Modena
- Azienda Ospedaliera Dei Colli - Ospedale Monaldi — Naples
- AOU dell'Università degli Studi della Campania Luigi Vanvitelli — Naples
- I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS — Rome
- Azienda Sanitaria Ospedaliera S Luigi Gonzaga — Torino
- Ospedale di Circolo — Varese
Germany · 4 centers
- Klinikum Chemnitz GmbH — Chemnitz
- KKH Grosshansdorf GmbH — Großhansdorf
- Thoraxklinik-Heidelberg gGmbH — Heidelberg
- Klinik Löwenstein GmbH — Löwenstein
United States · 3 centers
- Holy Cross Health — Fort Lauderdale
- The Ohio State University Wexner Medical Center — Columbus
- Vanderbilt University Medical Center — Nashville
Canada · 3 centers
- Ottawa Hospital General Campus — Ottawa
- Princess Margaret Cancer Centre — Toronto
- British Columbia Cancer Agency (6864) — Vancouver
Netherlands · 3 centers
- VU Medisch Centrum — Amsterdam
- Universitair Medisch Centrum Groningen - Department of Medical Oncology — Groningen
- Leiden University Medical Center — Leiden
Portugal · 3 centers
- Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria — Lisbon
- Centro Hospitalar do Porto E.P.E. Hospital de Santo António — Porto
- Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS — Porto Covo
Austria · 2 centers
- Klinikum Klagenfurt Am Woerthersee — Klagenfurt
- Klinik Floridsdorf — Vienna
Belgium · 2 centers
- AZ Delta — Roeselare
- AZ Nikolaas — Sint-Niklaas
Czechia · 2 centers
- FN Olomouc — Olomouc
- University Hospital Na Bulovce — Prague
Sweden · 1 center
- Universitetssjukhuset i Linköping — Linköping
Publications
- Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan PMID 39836056
Identifiers
NCT: NCT05376891 · MS200095_0050